NCT03678259View on ClinicalTrials.gov

124I-p5+14 Injection Safety in Subjects With Systemic Amyloidosis

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

57

Participants

Timeline

Start Date

October 1, 2018

Primary Completion Date

October 1, 2021

Study Completion Date

October 1, 2021

Conditions
Systemic Amyloidosis
Interventions
DRUG

124I-p5+14 Injection

124I-p5+14 Injection which is a formulation of a synthetic, all natural, 45 amino acid peptide (MW = 4766.4) with a net +12 positive charge

Trial Locations (1)

37920

University of Tennessee Medical Center, Knoxville

All Listed Sponsors
lead

University of Tennessee Graduate School of Medicine

OTHER

NCT03678259 - 124I-p5+14 Injection Safety in Subjects With Systemic Amyloidosis | Biotech Hunter | Biotech Hunter